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Abstract 
Introduction: Connective tissue diseases (CTDs) of childhood are rare inflammatory disorders, involving various organs and 
tissues including respiratory system. Pulmonary involvement in patients with CTDs is uncommon but may cause functional 
impairment. Data on prevalence and type of lung function abnormalities in children with CTDs are scarce. Thus, the aim of this 
study was to asses pulmonary functional status in children with newly diagnosed CTD and follow the results after two years of 
the disease course. 
Material and methods: There were 98 children (mean age: 13 ± 3; 76 girls), treated in Department of Pediatric Rheumatology, In-
stitute of Rheumatology, Warsaw and 80 aged-matched, healthy controls (mean age 12.7 ± 2.4; 50 girls) included into the study. 
Study procedures included medical history, physical examination, chest radiograph and PFT (spirometry and whole body-plethy-
smography). Then, the assessment of PFT was performed after 24 months. 
Results: FEV1, FEV1/FVC and MEF50 were significantly lower in CTD as compared to control group, there was no difference in 
FVC and TLC. The proportion of patients with abnormal lung function was significantly higher in the study group, 41 (42%) vs 9 
(11%). 24-months observation didn’t reveal progression in lung function impairment.
Conclusions: Lung function impairment is relatively common in children with CTDs. Although restrictive ventilatory pattern is 
considered typical feature of lung involvement in CTDs, airflow limitation could also be an initial abnormality.
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Introduction
Connective tissue diseases (CTDs) of child-
hood are rare inflammatory autoimmune disor-
ders affecting most commonly joints, muscles 
and skin. In many cases they are related to other 
organs manifestation, including the eyes, heart, 
lungs, kidneys, gastrointestinal tract, and blood 
vessels [1]. Pulmonary complications are infre-
quent in the childhood CTDs but may cause 
functional impairment and increase mortality 
[2]. Moreover CTDs treatment may also affect 
respiratory tract. Pulmonary involvement in chil-
dren may be symptomatic or clinically silent and 
manifests only as an abnormal diagnostic tests. 
Although rare, but most commonly observed is 
diffuse parenchymal lung disease which can 
be observed in almost every condition from the 
spectrum of rheumatic diseases. Other include 
pleurisy, typical for systemic lupus erythemato-
sus (SLE) and juvenile idiopathic arthritis (JIA), 
pulmonary hemorrhage, shrinking lung syndrome 
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or pulmonary arterial hypertension, which is ma-
jor cause of mortality in systemic scleroderma and 
mixed connective tissue disease [3]. In localized 
scleroderma, considered as a disease of the skin 
and subcutaneous tissue, respiratory involvement 
is also reported. The prevalence and clinical fe-
atures of extracutaneus manifestations in a large 
cohort of children (750 patients) were confirmed 
in 22.4% patients, and respiratory involvement 
in 2.6% of them [4].
In adults, involvement of the respiratory 
system is a common manifestation of CTD. Al-
though some characteristic clinical and radio-
logical patterns are recognized, the respiratory 
system may be involved in all its components: 
airways, vessels, parenchyma, pleura, respiratory 
muscles. Pulmonary symptoms in a patient with 
a known CTD require a prompt and systematic 
work-up, thus the diagnosis include wide range 
of procedures as imaging studies, bronchoscopy, 
lung function tests and sometimes lung biopsy [5].
Detection of pulmonary complication in chil-
dren with CTDs is based on the same procedures 
as in adults, but for some reasons is more com-
plicated. Diagnostic process include basic chest 
radiography, and more relevant high resolution 
computed tomography (HRCT). Although very 
sensitive technique but related to high doses of 
radiation. The other, invasive procedure is bron-
choalveolar lavage, indicated only in cases with 
respiratory symptoms and signs. The widely used 
screening method is pulmonary function tests 
(PFTs), however in pediatric population related to 
some limitations caused by the lack of a child-in-
vestigator cooperation. Since it is non-invasive 
and relatively cheap, PFTs are invaluable as a 
screening test of general respiratory health and 
are extensively used procedure in the diagnostic 
process in many conditions, which can affect 
respiratory system, even in asymptomatic pa-
tients. Albeit respiratory function in adults with 
CTD has been extensively investigated, relatively 
small number of studies including small groups 
of patients have been carried out in children 
[6−13]. Thus, the authors conducted this study 
to asses pulmonary functional status in children 
with newly diagnosed CTD and follow the results 
after two years of the disease course. 
Material and methods
Study population 
Ninety-eight children (mean age: 13 ± 3; 76 
girls and 22 boys), treated in Department of Pe-
diatric Rheumatology, Institute of Rheumatology, 
Warsaw and 80 aged-matched, healthy control 
subjects (mean age 12.7 ± 2.4; 50 girls and 30 
boys) were enrolled into the study. 
Diagnosis of CTD was made according to com-
monly accepted criteria. These included: American 
College of Rheumatology Classification Criteria for 
systemic lupus erythematosus (year 1982, revised 
in 1997) and American College of Rheumatology 
Criteria for systemic scleroderma (1980) [14, 15]. 
Nelson criteria were used to diagnose localized 
scleroderma (LS) and Kasukawa’s criteria (1988) to 
diagnose mixed connective tissue disease (MCTD) 
[16, 17]. Diagnosis of juvenile dermatomyositis 
(JDM) was based on Bohan and Peter criteria from 
1975 and 2006 international consensus [18, 19]. 
Scleromyositis (SCL) was diagnosed in patients 
presenting symptoms of both: SS and polymyositis 
and in whom serological marker anti-PM/Scl was 
detected. Diagnosis of undifferentiated connective 
tissue disease (UCTD) required demonstration of 1) 
signs and symptoms consistent with CTDs but not 
fulfilling the classification criteria for any defined 
CTDs and 2) detection of antinuclear antibodies in 
serum for at least 3 years. 
Study group consisted of: 30 children with 
LS and 14 with SS, 22 with UCTD, 14 children 
with SCL,14 children with MCTD, 2 with DM, 
and 2 children with SLE. 
The control group was recruited from the 
healthy school children. Children with any re-
spiratory signs and symptoms were excluded.
Study protocol
This prospective observational study was 
performed between January 2006−December 
2010. All patients entered the study within 4 
weeks from the diagnosis of CTD and were follo-
wed-up for at least 24 months. Initial evaluation 
performed at the time of study entry included 
medical history, physical examination, chest 
radiograph and lung function tests. 
Then, the course of the disease and manage-
ment were followed up and second assessment of 
lung function tests was performed after 24 months. 
All patients underwent spirometry with flow- 
-volume curve analysis (Spirometer Lungtest 
1000, MES, Poland) as well as whole body-plethy-
smography (Bodyplethysmograph Lungtest 1000, 
MES, Poland). Following parameters were me-
asured during lung function testing: forced vital 
capacity (FVC), forced expiratory volume in 1 
second (FEV1), maximal expiratory flow at 50% 
and 25% of vital capacity (MEF50 and MEF25, 
respectively). Total lung capacity (TLC) was me-
asured by body plethysmography. All pulmonary 
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function parameters are presented as the number 
of standard deviations (SD) from reference value 
(z-score). The lower limit of normal (LLN) for 
FVC, FEV1, FEV1/FVC, MEF25, MEF50 and TLC 
was set at (−1.96) SD below the calculated refe-
rence value. Similarly, airway obstruction was 
diagnosed if z-score for FEV1/FVC ratio was below 
(−1.96) SD. Abnormal small airways flow was 
defined as MEF50 and MEF25 z-score lower than 
(−1.96) SD. Restrictive ventilatory defect was dia-
gnosed when TLC z score was below (−1.96) SD.
Statistical analysis
Statistical analysis was performed with STA-
TISTICA software, version 10.0 (StatSoft, Tulsa, 
OK, USA). Variables were expressed as mean and 
standard deviation. Differences between variables 
in two groups were tested with nonparametric 
Mann-Whitney U test and Kruskal-Wallis ANOVA 
for more than 2 groups. The Chi-squared test 
(Fisher’s test, Mc Nemar’s test) was used to assess 
the proportions of patients with abnormal results 
of different parameters in the control and in the 
study group. Wilcoxon rank test was applied to 
compare results at the baseline and after 2 years. 
All P values were 2-tailed and p < 0.05 was con-
sidered statistically significant.
Ethical considerations
The study protocol was accepted by Insti-




There were no children complaining of dys-
pnea or exercise limitation. Seven of 98 children 
Table 1.  Lung function results in study and control group presented as z-score 
Study group Control subjects p
Age (year) ± SD 13.01 ± 2.99 12.72 ± 2.38 NS
Height (cm) ± SD 151.3 ± 14.9 156.2 ± 13.9 0.002
FVC* ± SD −0.52 ± 1.7 −0.62 ± 1.1 NS
FEV1* ± SD −1.56 ± 1.7 −0.51 ± 1.1 0.000
FEV1/FVC* ± SD −0.98 ± 1.8 0.24 ± 1.2 0.000
MEF50* ± SD −1.8 ± 3.0 −0.77 ± 1.2 0.0049
MEF25 * ± SD −0.31 ± 1.5 −0.19 ± 0.9 0.058
TLC* ± SD 0.41 ± 1.9 0.1 ± 1.8 0.461
FEV1 — forced expiratory volume in 1 second; FVC — forced vital capacity; FEV1/FVC ratio; MEF50 — maximal expiratory flow at 50% of vital capacity; MEF25 — maxi-
mal expiratory flow at 25% of vital capacity; TLC — total lung capacity; NS — not significant; SD — standard deviation;*lung function measures presented as z-scores
(7%) presented with chronic cough, 10 (10%) 
had recurrent upper respiratory tract infections. 
Physical examination revealed wheezing in 
one patient. No other signs of respiratory diseases 
were found.
Imaging 
The chest x- ray was abnormal in 2 cases. In 
both patients discrete pleural thickenings were 
detected. 
Lung function
The results of spirometry and whole body
-plethysmography in both, study and control 
group are presented in Table 1. 
There were differences in FEV1, FEV1/FVC 
and MEF50 expressed as z-scores in the study gro-
up as compared to healthy subjects (−1.56 ± 1.7 
vs −0.51 ± 1.1; −0.98 ± 1.8 vs 0.24 ± 1.2; −1.8 
± 3.0 vs −0.77 ± 1.2 respectively). The values 
measured in the study group were significantly 
lower than the respective values in controls.
Significant differences were also demonstra-
ted in the percentage of patients with the results 
below the LLN. The proportion of patients with 
abnormal lung function was significantly higher 
in the study group than the healthy controls. 
Functional lung impairment defined as FVC or 
FEV1 or FEV1/FVC below LLN was found in 41 
(42%) children with CTD and only in 9 (11%) con-
trols. There was only one patient in study group 
with decreased FEV1 and FVC but with normal 
TLC. The prevalence of various lung function 
abnormalities in both groups, including p-values, 
ORs and CIs are presented in Table 2. 
Spirometry results aggregated according to 
the diagnosis are presented in Table 3. Subgroup 
analysis showed differences for FVC (p = 0.041) 
but not for TLC. Further statistical analysis — 
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Table 2. Abnormal lung function results observed in study and control group 
Parameter
Number (percentage) of the results below LLN
Chi-square OR (CI)Study group Control group
FVC 14 (14) 7 (9) NS NA
FEV1 35 (36) 7 (9) p = 0.00
OR 5.79
( 2.41–13.95)
FEV1/FVC 27 (28) 2 (3) p = 0.00
OR 14.31
(3.4–64.62)
MEF 50 34 (35) 13 (17) p = 0.0055
OR 2.74
(1.32–5.65)
MEF 25 11 (12) 0 (0) p = 0.02
TLC 5 (6) 2 (3) NS NA
SD — standard deviation; OR — odds ratio; CI — confidence interval; NS — not significant; LLN — lower limit of normal; FEV1 — forced expiratory volume in 1 
second; FVC — forced vital capacity; FEV1/FVC ratio; MEF50 — maximal expiratory flow at 50% of vital capacity; MEF25 — maximal expiratory flow at 25% of vital 
capacity; TLC — total lung capacity
Table 3. Age and lung function tests results in study group according to the diagnosis of CTD 
UCTD MCTD LS SS SCL DM SLE p
N 22 14 30 14 14 2 2
AGE (years) ± SD 14.8 ± 1.7 13.5 ± 2.7 11.2 ± 3.2 13.2 ± 2.7 12.6 ± 2.9 17.0 ± 1.2 13.5 ± 0.7 0.009
FVC* ± SD −0.7 ± 1.7 −0.46 ± 2.2 0.12 ± 1.5 −0.8 ± 1.5 −0.97 ± 1.3 1.5 ± 0.4 −2.4 ± 1.2 0.041
FEV1* ± SD −1.5 ± 1.5 −1.4 ± 2.6 −1.3 ± 1.7 −1.4 ± 1.6 −1.8 ± 1.4 −4.3 ± 0.9 −3.2 ± 0.7 NS
FEV1/FVC* ± SD −0.5 ± 1.6 −0.9 ± 1.3 −1.75 ± 2.0 −0.33 ± 1.3 −0.5 ± 1.6 −3.8 ± 2.2 −0.4 ± 1.2 NS
MEF50* ± SD −0.9 ± 2.0 −2.7 ± 3.8 −1.4 ± 2.6 −1.3 ± 2.1 −1.4 ± 1.9 −12.0 ± 2.9 −7.1 ± 1.1 NS
MEF25* ± SD −0.02 ± 1.2 −0.6 ± 1.3 −0.4 ± 1.6 0.13 ± 1.3 0.15 ± 1.1 −0.7 ± 0.1 −1.7 ± 0.7 NS
TLC* ± SD 0.39 ± 1.7 0.4 ± 2.2 0.8 ± 2.3 0.3 ± 1.4 −1.4 ± 0.9 −0.7 ± 1.1 −2.0 ± 1.3 NS
UCTD — undifferentiated connective tissue disease; MCTD — mixed connective tissue disease; LS — localized scleroderma; SS — systemic sclerosis; SCL — sc-
leromyositis; DM — dermatomyositis; SLE — systemic lupus erythematosus; FEV1 — forced expiratory volume in 1 second; FVC — forced vital capacity; FEV1/FVC 
ratio; MEF50 — maximal expiratory flow at 50% of vital capacity; MEF25 — maximal expiratory flow at 25% of vital capacity; TLC — total lung capacity; NS — not 
significant; SD — standard deviation; *lung function measures presented as z-scores
multiple group comparisons showed no signifi-
cant differences. 
We did not find any abnormalities in lung 
function tests in children with chronic cough and 
recurrent respiratory tract infections.
Patient management and follow-up 
Appropriate pharmacological treatment had 
been undertaken in 98 children. This included: 
systemic corticosteroids (28 patients), antimalari-
als (chloroquine phosphate, hydroxychloroqiune) 
(29 patients), sulfa drugs (sulfasalazine) (2 pa-
tients) nonsteroidal anti-inflammatory drugs (7 
patients), chelator (penicylamine) (11 patients), 
vasodilators (buflomedil hydrochloride, xantinoli 
nicotinate, pentoxifilline) (27 patients), herbal 
supplements (piascledine — extract of soybean 
and avocado) (65 patients) and vitamins (A, E, PP) 
(33 patients). The respective therapeutic regimens 
and drug doses were at the discretion of the atten-
ding physicians and were adjusted individually 
according to disease stage and activity. 
After two years of follow-up 89 children un-
derwent second lung function testing. None of the 
parameters differed significantly when compared 
to the baseline results. 
Discussion
Our study showed pulmonary functional 
impairment in children with CTD. The overall 
proportion of abnormal spirometry results was 
almost 4-fold higher in our study group than in 
age-matched healthy controls. This was even 
more significant in respect to some lung function 
parameters including FEV1 and FEV1/FVC. 
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Unexpectedly, predominant spirometric 
abnormalities found in children with CTD were 
suggestive for decreased airflow rather than for 
reduced lung volumes. Almost 36% of patients 
presented abnormal FEV1, 27.5% had significantly 
decreased FEV1/FVC and 34.7% showed decreased 
flow in small airways. This is in  contrast to some 
previous studies which demonstrated mainly 
restrictive ventilatory pattern [5, 7, 20]. It must 
be admitted, however, that the majority of data 
on impaired lung function in CTD comes from 
studies which were performed in adults. 
Although CTDs occur at all ages, the highest 
prevalence was found in young adults in the age 
group between 15−40 years, with female-male 
ratio 6−10: 1 [21]. The prevalence of CTDs in 
children, especially those below the age of 15 
years is significantly lower. Thus, the number of 
studies on lung disease in children with CTDs 
is relatively low. As the number of children par-
ticipating in these studies is usually small and 
pulmonary involvement in this age group is rare, 
the data on lung diseases in children with CTDs 
are relatively scarce. In this context our study 
which involved relatively large group of patients 
may add to the existing literature. 
In one early study which included 62 chil-
dren with various CTDs (juvenile rheumatoid 
arthritis, juvenile dermatomyositis, systemic 
lupus erythematosus and overlap syndrome), 
decreased VC and diffusing lung capacity for 
carbon monoxide (DLCO) were demonstrated in 
most patients with active disease. While in all 
studied CTD patients during disease remission 
PFT results did not significantly differ from nor-
mal controls. No case of airway obstruction was 
detected in study group [7].
Restrictive ventilatory pattern was also found 
by Trapani et al., who investigated the prevalen-
ce of asymptomatic pulmonary involvement in 
children with juvenile DM. These authors fol-
lowed a small group of 12 children and showed 
restrictive pattern of impairment in 5 patients. 
Two had reduced FVC, FEV1, MEF25, DLCO and 
single-breath alveolar volume (VA); one patient 
also had reduced MEF50. Two children showed 
a slight reduction of VA [8].
Recently, Alkady et al. reported the results of 
the study aimed at early diagnosis of cardiac and 
pulmonary involvement in children with juvenile 
idiopathic arthritis. Although the study group was 
relatively large and included 45 children it was 
still much smaller than our group of 98 patients. 
It should be emphasized that, similarly to our 
study, this study included control group. Regar-
ding pulmonary function, the authors found that 
children with juvenile idiopathic arthritis (JIA) 
were characterized by decreased FVC, peak expi-
ratory flow, maximal inspiratory and expiratory 
pressure as well as reduced DLCO. Spirometric 
abnormalities were associated with some featu-
res of the disease. These included: rheumatoid 
factor titer, erythrocyte sedimentation rate, di-
sease duration and the duration of methotrexate 
use. Significant inverse correlation was reported 
between the above parameters and pulmonary 
function measures [9].
A small study conducted by Quezada et al. 
showed lung involvement in 4 of 14 children with 
CTDs. Restrictive defect of lung function was de-
monstrated in one patient with SLE. The authors 
recommend routine checks of pulmonary function 
in all patients with rheumatologic diseases even 
in the absence of respiratory symptoms [10].
Although restrictive ventilatory pattern was a 
predominant lung function abnormality in above 
mentioned studies, there are also studies which 
show that CTDs might be associated with airway 
obstruction. In multicenter prospective study on 
juvenile DM, pulmonary function impairment 
was found in 7 (35%) of twenty patients. Obs-
tructive and restrictive ventilatory defect was 
diagnosed in three and four patients, respectively. 
Three patients had an isolated obstructive ven-
tilatory defect, and two of them did not respond 
to a short acting beta-2 agonist [22].
Airflow limitations in patients with CTDs 
were also reported by Lilleby et al. The study was 
performed in a cohort of 60 young adults (mean 
age 28.1 ± 9.5 years and mean disease duration 
12.0 ± 8.3 years) with childhood onset SLE. Ove-
rall prevalence of abnormal PFT results was 37% 
(17/46). FVC was reduced in six patients (10%), 
and FEV1 was abnormal in nine (15%) patients. 
Obstructive and restrictive abnormality was seen in 
three (7%) and one (2%) patients, respectively [11].
The prevalence of airway involvement in 
patients with CTDs seems to be closely related 
to the underlying diseases. It is uncommon in 
SLE, but in Sjögren syndrome — the prevalence 
of airway disease is higher than the prevalence 
of interstitial lung disease. Nevertheless, rare 
cases of bronchiolitis obliterans with organizing 
pneumonia (BOOP) have been reported in pa-
tients with SLE. BOOP lesions are characterized 
histologically by inflammatory changes within 
the distal airways and alveoli associated with 
nonspecific bronchiolar inflammation [23].
In patients with Sjögren syndrome bronchio-
litis and bronchiectasis are the most common 
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pulmonary manifestations [24]. In MCTD and sys-
temic sclerosis progressive oesophageal dysmoti-
lity increases the risk of aspiration pneumonia, 
chronic aspiration-associated bronchoconstric-
tion, and/or mild pulmonary fibrosis [25, 26]. 
Our study showed that in children with 
CTDs airway obstruction is more common than 
restrictive ventilatory pattern (27,5% vs 6%). This 
could rise a question, whether this observation 
was not confounded by coexistence of asthma. 
Asthma is the most prevalent chronic disease in 
children and the most common cause of obstructi-
ve ventilatory defect among pediatric population. 
The concomitance of asthma and CTD has been 
observed in adult patients. The case-control stu-
dy from Taiwan showed that asthma and other 
allergic diseases were two-fold more common in 
patients with SLE as compared to controls [27]. 
An Australian study that evaluated comorbidity 
among senior Australians revealed a common co-
existence of arthritis with asthma and bronchitis 
[28]. Our results in children do not support the 
association between CTDs and asthma. None of 
the patients with CTD had a history of asthma. 
Children with obstructive ventilatory pattern had 
no dyspnea, exercise limitation, chronic cough 
or recurrent wheeze. However, we have to admit 
that reversibility test was not performed. This fact 
is mentioned as a study limitation. On the other 
hand, since asthma had not been diagnosed in 
any of CTD patients during two-year follow up, 
we might speculate that bronchial obstruction 
was probably not related to asthma. 
In our study group, abnormal lung function 
was significantly more common than structural 
changes assessed in chest radiographs. There 
were no children with radiological signs of inter-
stitial lung diseases and the only abnormalities 
revealed by chest radiographs were mild pleural 
thickening demonstrated in two children (2%). 
This seems to be consistent with the observations 
previously made in young adults with CTDs. 
Lilleby et al. reported low frequency of HRCT 
abnormalities (8%). They found micronodules 
in 4 patients and bronchiectasis in one, but none 
radiographic evidence of ILD. The authors conc-
lude that asymptomatic children with SLE do not 
require HRCT investigation [11].
Interestingly, pulmonary function reassess-
ment performed after two years did not revealed 
difference when compared to baseline results. 
This was also the case in the study by Cerveri et 
al. who compared baseline and follow-up results 
of pulmonary function tests in 15 children with 
SLE. The mean time interval between the baseline 
and repeated tests was 4,5 years. The authors ob-
served even improving trends in lung functions. 
Therefore, they concluded that the presence of 
early isolated functional abnormalities was not 
associated with subsequent development of lung 
disease [12]. As we did not observed any deterio-
ration in the results of pulmonary function tests 
after two years of follow-up, we may speculate 
that neither the disease nor the pharmacological 
treatment negatively affected lung function. Ho-
wever, we realize that this observation could have 
been biased by relatively short time of follow up. 
We are aware about several limitations of 
our study. First, significant heterogeneity of our 
study group should be mentioned. This refers not 
only to wide spectrum of CTDs but also uneven 
distribution of different clinical entities. Nearly 
one third of patients suffered from localized sc-
leroderma, while there were only 2% of patients 
with SLE and DM. Thus, although we analyzed 
the results in the context of underlying diseases 
we believe this is not justified to draw unequivo-
cal conclusions. Second, our pulmonary function 
assessment has not included DLCO measurement. 
Decreased DLCO is regarded as an early marker of 
interstitial lung involvement. Reduced DLCO has 
been demonstrated in earlier studies in patients 
with CTDs [29]. Third, reversibility of airflow 
limitation has not been tested in patients with 
obstructive ventilatory pattern. Measurement of 
airflow parameters after inhalation of broncho-
dilators could have allowed for more in-depth 
analysis of the nature of bronchial obstruction. 
Finally, two years follow-up might have been too 
short to demonstrate CTD associated deterioration 
in lung function. 
Conclusions 
In conclusion, lung function impairment 
is relatively common in children with CTDs. 
Thus, these patients should undergo pulmonary 
function assessment at the time of CTD dia-
gnosis and further in the course of the disease. 
Although restrictive pattern of lung function is 
considered as typical feature of lung involve-
ment in CTDs, airflow limitation could also be 
an initial abnormality. This observation warrants 
further studies. 
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